Polaris Management Partners

Title	Description
Balancing Act Rx Compliance September 2006	With the federal government and states introducing new regulations governing medical education, companies must interpret the rules and manage the risk.
Orchestrating Compliance Pharmaceutical Executive October 2005	Compliance officers must remain vigilant as new risks emerge. Presented in this article are 7 risk areas to place high on the agenda in the coming years.
Preparing for Compliance in All 50 States Pharmaceutical Executive September 2005	Five things you can do to prepare for compliance in all 50 states — starting today.
Fair Market Value for Physician Consultants Pharmaceutical Executive September 2005	Pharmas pay doctors hundreds of millions of dollars a year to tell colleauges about drugs. Warning of potential fraud and abuse, the OIG set guidelines for fees. But even compliant companies may face tough lawsuits unless they can prove they pay fair market value for physician consultants.
Crafting a Global Compliance Strategy Rx Compliance Report March 2005	Scrutiny of Pharma sales and marketing practices mounts worldwide. European regulatory trends pose a serious challenge to U.S. companies.
States Won't Wait for Feds Pharmaceutical Executive March 2005	States appear to be focused on two areas: codifying existing guidance, and requiring the disclosure of pharmaceutical marketing expenditures.
Demystifying Fair Market Value Determination Rx Compliance Report July 2004	What is fair market value for a physician's time and service? Although the OIG created the FMV mandate, it has not provided clear guidelines for making such payment determinations.
Taking Aim: The Case for Targeting Internal Compliance Audits Rx Compliance Report April 2004	Some pharmaceutical companies have limited insight into their key risk areas. As a result, they struggle to uncover compliance issues using broad-based auditing techniques.
Drawing a Line in the Brand Pharmaceutical Executive October 2003	Vendors must establish boundaries between CME and promotion.
Pharmaceutical Execs Look to Benchmarking April 2003	The virtues of implementing a benchmarking database in medical education and the perils of obtaining acceptance for using the database
CME Providers Court Peril by Ignoring New Compliance Guidelines February 2003	It is just a matter of time until the pharmaceutical companies will request more active participation in auditing CME programs from accredited providers.